BeOne Medicines - Public Comps and Valuation Multiples

BeOne Medicines Overview

About BeOne Medicines

Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne’s revenue.

Founded

2010

HQ

Employees

11K+

Website

beonemedicines.com

Sectors

Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $4.9B

LTM EBITDA $195M

EV

$38.7B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

BeOne Medicines Financials

As of September 2025, BeOne Medicines reported last 12-month revenue of $4.9B and EBITDA of $195M.

In the same period, BeOne Medicines generated $4.2B in LTM gross profit and $8.3M in net income.

See BeOne Medicines valuation multiples based on analyst estimates

BeOne Medicines P&L

In the most recent fiscal year, BeOne Medicines reported revenue of $490M and EBITDA of -$50.9M.

BeOne Medicines expects next 12-month revenue of XXX and NTM EBITDA of XXX

See BeOne Medicines valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$4.9B	XXX	$490M	XXX	XXX	XXX
Gross Profit	$4.2B	XXX	$413M	XXX	XXX	XXX
Gross Margin	86%	XXX	84%	XXX	XXX	XXX
EBITDA	$195M	XXX	-$50.9M	XXX	XXX	XXX
EBITDA Margin	4%	XXX	-10%	XXX	XXX	XXX
EBIT	$59.4M	XXX	-$73.0M	XXX	XXX	XXX
EBIT Margin	1%	XXX	-15%	XXX	XXX	XXX
Net Profit	$8.3M	XXX	-$82.8M	XXX	XXX	XXX
Net Margin	0%	XXX	-17%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for BeOne Medicines including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $4.9B. EBITDA for the last twelve months was $195M. In the most recent fiscal year, BeOne Medicines achieved $490M in revenue and -$50.9M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$4.9B	Analyst estimates available to subscribers	$490M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$4.2B	Analyst estimates available to subscribers	$413M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	86.2% gross margin	Analyst estimates available to subscribers	84.4% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$195M	Analyst estimates available to subscribers	-$50.9M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	4.0% EBITDA margin	Analyst estimates available to subscribers	-10.4% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$59.4M	Analyst estimates available to subscribers	-$73.0M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	1.2% EBIT margin	Analyst estimates available to subscribers	-14.9% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$8.3M	Analyst estimates available to subscribers	-$82.8M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	0.2% net profit margin	Analyst estimates available to subscribers	-16.9% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for BeOne Medicines

This financial data table provides comprehensive performance metrics for BeOne Medicines, a company based in Hong Kong. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

BeOne Medicines generated $4.9B in revenue over the last twelve months.
The company achieved $195M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $4.2B.
Net income over the last twelve months reached $8.3M.

Fiscal Year Performance

In the most recent fiscal year, BeOne Medicines reported $490M in total revenue.
Fiscal year EBITDA was -$50.9M.
The company maintained a gross profit margin of 84.4% in the most recent fiscal year.
EBITDA margin for the fiscal year was -10.4%.
Net profit margin reached -16.9% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for BeOne Medicines. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

BeOne Medicines Stock Performance

BeOne Medicines has current market cap of HKD 315B (or $40.5B), and EV of HKD 301B (or $38.7B).

Market Cap Evolution

BeOne Medicines Stock Data

As of October 3, 2025, BeOne Medicines's stock price is HKD 220 (or $28).

See BeOne Medicines trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$38.7B	$40.5B	XXX	XXX	XXX	XXX	$0.03

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

BeOne Medicines Valuation Multiples

BeOne Medicines's trades at 79.1x EV/Revenue multiple, and -760.2x EV/EBITDA.

See valuation multiples for BeOne Medicines and 15K+ public comps

BeOne Medicines Financial Valuation Multiples

As of October 3, 2025, BeOne Medicines has market cap of $40.5B and EV of $38.7B.

Equity research analysts estimate BeOne Medicines's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

BeOne Medicines has a P/E ratio of 4856.0x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$40.5B	XXX	$40.5B	XXX	XXX	XXX
EV (current)	$38.7B	XXX	$38.7B	XXX	XXX	XXX
EV/Revenue	7.9x	XXX	79.1x	XXX	XXX	XXX
EV/EBITDA	198.6x	XXX	-760.2x	XXX	XXX	XXX
EV/EBIT	652.3x	XXX	-530.4x	XXX	XXX	XXX
EV/Gross Profit	9.2x	XXX	n/a	XXX	XXX	XXX
P/E	4856.0x	XXX	-488.3x	XXX	XXX	XXX
EV/FCF	606.7x	XXX	-449.9x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get BeOne Medicines Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

BeOne Medicines Margins & Growth Rates

BeOne Medicines's revenue per employee in the last FY averaged $45K, while opex per employee averaged $44K for the same period.

BeOne Medicines's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

BeOne Medicines's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for BeOne Medicines and other 15K+ public comps

BeOne Medicines Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	n/a	XXX	261%	XXX	XXX	XXX
EBITDA Margin	4%	XXX	-10%	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	n/a	XXX	XXX	XXX
Rule of 40	n/a	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$45K	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$44K	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	51%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	99%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial